finance.yahoo.com
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn's ...
The story describes a new drug mechanism (dCK inhibition) that reduced inflammation in an IBD mouse model, which could point to a different way to target overactive immune cells in Crohn’s disease. It’s early-stage preclinical research, so it won’t change patient care now but may inform future clinical trials.
Researchers and clinicians interested in IBD drug development, and patients following emerging therapies for Crohn’s disease or autoimmune-targeted metabolic approaches.
What To Know
Trethera issued a paid press release announcing a poster at the Crohn’s & Colitis Congress about preclinical IBD work with TRE-515, a first-in-class oral deoxycytidine kinase (dCK) inhibitor.
The company reports that TRE-515 reduced inflammation and limited activated CD4 T cell proliferation in an adoptive CD4 transfer mouse model, and notes TRE-515 is in Phase 1 testing for solid tumors. This is a preclinical poster (mouse model) presented by Trethera and academic co-authors; it does not report human trial results for IBD.
The announcement connects the mechanism (dCK/nucleoside salvage) to both autoimmune T cell proliferation and cancer biology, and highlights prior related work and imaging examples shown in figures.
If you want to read the primary data, look for the poster at the CCC meeting or subsequent peer-reviewed publications; the press release is a company-funded summary and includes forward-looking statements.
This is a company press release about a poster presentation of preclinical mouse-model data; TRE-515 is in Phase 1 trials for cancer, not yet in human IBD trials. Company press releases summarize and promote research findings—look for the full poster or peer-reviewed study for methods and data before drawing conclusions.
